Top German diplomat criticizes China ahead of Japan, Indonesia visit
"Fundamental rules of our global coexistence are at stake here," he warned before his departure from the Hamburg Airport. This also has implications for Europe, he added.
Germany is countering this by advocating for "an international order based on the strength of the rule of law and binding rules for all."
Wadephul is scheduled to meet Japanese Prime Minister Shigeru Ishiba, Foreign Minister Takeshi Iwaya and several ministers responsible for economic affairs in Tokyo on Monday. A speech at a peace foundation is also planned.
"Our freedom, our prosperity and our security—the goals that guide me as foreign minister—are not decided in Europe alone. They are decided especially in cooperation with strong partners worldwide," the minister said, explaining the purpose of his trip.
Minister stresses importance of open sea routes
"The Indo-Pacific is crucial in determining how secure the freedom of sea routes, global supply chains and, consequently, the economic development of the entire world remains," Wadephul said.
This is of paramount importance for major exporting economies like Germany and Japan, as well as for emerging partners in the Association of Southeast Asian Nations (ASEAN), such as Indonesia, he said.
Germany's foreign minister is set to visit Indonesia on Wednesday.
He criticized China for challenging the economies of Germany and Japan with unfair and market-distorting trade practices. He also noted that US tariff policies are unsettling businesses in Europe and Asia.
Germany, he said, is working with key partners like Japan and Indonesia to promote economic relations based on free trade, competition and fairness. Germany shares more with Japan than with almost any other country in the Indo-Pacific region, the minister added.
"We are united by values and interests, and we face the same massive challenges that call our liberal way of life into question."
Solve the daily Crossword
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
8 minutes ago
- Yahoo
XtalPi Holdings Limited to Announce 2025 Interim Results on August 27, 2025
CAMBRIDGE, Mass., Aug. 18, 2025 /PRNewswire/ -- XtalPi Holdings Limited ("XtalPi", or the "Company") (HKEX: 2228), a leading global technology company in integrating artificial intelligence (AI) and robotics for drug and materials discovery, announced that it will report its interim results for the six months ended June 30, 2025 on Wednesday, August 27, 2025, after the Hong Kong market closes. The Company will hold a conference call in Chinese with English simultaneous interpretation at 7:00 PM Hong Kong/Beijing Time on August 27, 2025 (7:00 AM U.S. Eastern Time on the same day). Details for the conference call are as follows: For Chinese original audio channel: Online Registration Link: Alternatively, participants may access the conference call by dialing the following numbers: Mainland China: +86-4001510269 International: +86-1021377168 Hong Kong, China: +852-51089680 Taiwan, China: +886-277083288United States: +1-2087016888Password: 197788The replay of the conference call will be available on the Company's investor relations website at For English simultaneous interpretation channel: Online Registration Link: About XtalPi XtalPi Holdings Limited (XtalPi, was founded in 2015 by three physicists from the Massachusetts Institute of Technology (MIT). It is an innovative R&D platform powered by quantum physics, artificial intelligence, and robotics. By integrating first-principles calculations, AI algorithms, high-performance cloud computing, and standardized automation systems, XtalPi provides digital and intelligent R&D solutions for companies in the pharmaceutical, materials science, agricultural technology, energy, new chemicals, and cosmetics industries. Investor Relations Contact: In China: XtalPi Holdings LimitedInvestor RelationsEmail: ir@ Piacente Financial CommunicationsTel: +86-10-6508-0677Email: XtalPi@ In the United States: Piacente Financial CommunicationsBrandi PiacenteTel: +1-212-481-2050Email: XtalPi@ View original content to download multimedia: SOURCE XtalPi Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
11 minutes ago
- Associated Press
Hubject Unveils icnc25 Agenda: Industry Leaders Unite to Shape Customer Experiences
Hubject's icnc25 agenda spotlights how industry leaders are bridging the gap from early adopters to mass EV adoption. 'This lineup represents the industry's most comprehensive exploration of how we transform technical capabilities into customer experiences that accelerate mass adoption'— Christian Hahn, Hubject CEO BERLIN, GERMANY, August 18, 2025 / / -- Hubject, the global leader in eMobility interoperability, today announced exciting agenda updates for icnc25, taking place September 2-4, 2025 at Berlin's historic Tempelhof Airport. The three-day eMobility event brings together 60+ global thought leaders and 6,000 industry experts to address this year's theme: 'Shaping Customer Experiences: Bridging the Gap to Mass EV Adoption.' The expanded three-day format reflects the industry's evolution from infrastructure deployment to delivering exceptional customer experiences that foster confidence and loyalty among mainstream consumers. The comprehensive agenda demonstrates how leading companies are transforming technical innovation into seamless charging experiences that meet and exceed driver expectations. 'This lineup represents the industry's most comprehensive exploration of how we transform technical capabilities into customer experiences that accelerate mass adoption,' said Christian Hahn, CEO of Hubject. 'From AI-powered operations to global fleet electrification, our speakers will demonstrate how the industry is moving beyond serving early adopters to creating charging ecosystems where all drivers feel empowered to embrace eMobility.' Industry Leaders Address Customer Experience Challenges The conference opens September 2nd with the Tech Village featuring hands-on demonstrations, before expanding to the main stages on September 3rd with major keynotes from AMPECO CEO Orlin Radev on 'Crossing the Chasm in EV Charging,' examining why the next 18 months will separate industry leaders from the rest. A high-level panel featuring Christian Hahn (Hubject), Stefan Ivanov (AMPECO) and Chris Heron (E-Mobility Europe),"Delivering for the School run Squad: Expectations for EV Charging.' Greenflux's Suthalan Gnanes will present 'No Excuses | Scaling the EV Ecosystem for Mass Adoption,' addressing how the industry must move beyond emerging market dynamics to prepare for mainstream EV adoption. EVailable's Maren Rehnelt addresses charger availability through AI-powered operations, while September 4th features ChargePoint's Andreas Blin presenting 'The Mass Adoption Blueprint,' showing how platform maturity enables industry-wide success. Critical discussions include 'Smart Energy Solutions & Bidirectional Charging – Ready for the Mass Market?' featuring Volvo, Octopus Energy, E3/DC, The Mobility House, and P3 Group, and 'Interoperability vs Fragmentation? Lessons Learned from Europe's Charging Networks' with speakers from Deftpower, Chargecloud, Tesla, and Bloom Charge. Global Expansion and Commercial Leadership The agenda addresses scaling customer experiences globally with panels on building international frameworks and commercial fleet adoption. The final day's 'Fleet First: How Commercial Vehicles Are Pioneering Mass EV Adoption' features experts from Improved Corporate Finance, Einride and Virtos, while E-ON presents strategies for seamless heavy-duty transport charging experiences. Throughout the three days, the Tech Village showcases hands-on demonstrations of breakthrough technologies including Plug&Charge, V2X, in-car digital experiences, truck reservations, and advanced interoperability testing designed to enable mass adoption scaling. Key sessions include technical deep-dives into bidirectional DC charging exploring V2G, V2H, and V2B applications, interoperable truck reservation systems featuring OCPI 2.3-based solutions with Hubject, FRYTE, and Bosch Road Services, and reliability approaches examining how data improvements and proactive monitoring enhance customer experiences. A highlight of the Tech Village is the live demonstration featuring a Ford Explorer, Ambibox, and Hubject, powering the Tech Village stage as a decentralized energy solution. Comprehensive Industry Engagement icnc25 features three distinct stages with strategic keynotes and technical sessions, plus the Innovation Zone with live demonstrations and the expanded Tech Village offering deep dives into emerging standards and real-world implementations. New this year, the official icnc25 Networking Breakfast kicks off Day 2 (September 3rd, 8:15-9:00 AM) in Hangar 7, providing additional opportunities for the eMobility community to connect over coffee and conversations before the main programming begins. The renowned Festival of eMobility evening reception creates opportunities for meaningful industry connections. AMPECO returns as Platinum Sponsor for icnc25. Elements of the event will be streamed online for global access, and additional sponsorship opportunities remain available. What started as a small hackathon in 2011 has grown into the most influential event in the EV charging industry, bringing together the full spectrum of stakeholders to collaborate on customer-centric EV charging solutions. Secure your place at icnc25 by visiting: Media Contact Stuart Barnes [email protected] Stuart Barnes Hubject +49 30 5870889113 email us here Visit us on social media: LinkedIn YouTube Legal Disclaimer: EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Associated Press
11 minutes ago
- Associated Press
KELUN-BIOTECH ANNOUNCES 2025 INTERIM RESULTS
CHENGDU, China, Aug. 18, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Pharmaceutical Co., Ltd. ('Kelun-Biotech' or the 'Company', Stock Code: announced its unaudited interim results for the six months ended 30 June 2025 (the 'Reporting Period'). In the first half of 2025, China's biopharmaceutical industry reached an inflection point for high-quality growth, driven by accelerated innovation in drug research and development, the rollout of favorable policies, increasing momentum in industry collaboration and mergers and acquisitions. Kelun-Biotech capitalized on these opportunities by its proprietary technology platforms, innovation-led R&D, and a well-established commercialization infrastructure. These elements have worked together to enable the Company to establish a fully integrated model covering R&D, clinical development, manufacturing, and commercialization. Focusing on addressing significant unmet medical needs in both oncology (such as breast cancer (BC), non-small cell lung cancer (NSCLC), and gastrointestinal (GI) cancers including gastric cancer (GC) and colorectal cancer (CRC)) and non-oncology diseases, the Company has developed a rich and diverse pipeline of over 30 candidates. More than 10 of these candidates have already entered clinical stage. At the same time, the Company continues to invest in next-generation conjugation technologies and a diversified portfolio of assets, aiming to deliver innovative therapies for patients worldwide and contribute to the improvement of global healthcare. ADC & novel DC assets breakthroughs are redefining the treatment landscape. sac-TMT (sacituzumab tirumotecan, SKB264/MK-2870,佳泰萊®) The first TROP2 ADC drug approved for marketing in LC globally. TNBC: Approved by the National Medical Products Administration ('NMPA') for the treatment of adult patients with unresectable locally advanced or metastatic TNBC who have received at least two prior systemic therapies. The Company has initiated a Phase 3 registrational study of sac-TMT monotherapy versus investigator-choice chemotherapy for 1L advanced TNBC. HR+/HER2- BC. In May 2025, the NDA for sac-TMT for the treatment of adult patients with unresectable locally advanced or metastatic HR+/HER2- BC who have received prior endocrine therapy and other systemic treatments in the advanced or metastatic setting was accepted by the NMPA, and was included in the priority review and approval process. A Phase 3 registrational study of sac-TMT versus investigator's choice of chemotherapy for treatment of patients with unresectable locally advanced, recurrent or metastatic HR+/HER2- BC who received prior endocrine therapy is in progress. EGFR-mutant NSCLC. In March 2025, the Company received marketing authorization in China from the NMPA for sac-TMT for the treatment of adult patients with EGFR mutant-positive locally advanced or metastatic non-squamous NSCLC following progression on EGFR-TKI therapy and platinum-based chemotherapy. Sac-TMT monotherapy demonstrated a statistically significant and clinically meaningful improvement in ORR, PFS and OS compared with docetaxel. In addition, a Phase 3 registrational study of sac-TMT combined with osimertinib as first-line treatment of locally advanced or metastatic non-squamous EGFR-mutant NSCLC is in progress. EGFR-wild type NSCLC. Two Phase 3 registrational studies of sac-TMT in combination with pembrolizumab are in progress. In June 2025, sac-TMT in combination with tagitanlimab was granted Breakthrough Therapy Designation by the NMPA for the first-line treatment of locally advanced or metastatic non-squamous NSCLC without actionable genomic alterations. Other indications. The Company is actively exploring the potential of sac-TMT both as a monotherapy and in combination with other therapies for treating other solid tumors, including GC, EC, CC, OC, UC, CRPC and HNSCC. Global clinical development. As of August 18, 2025, MSD is progressing 14 ongoing Phase 3 global, multi-center clinical studies for sac-TMT for several types of cancer including BC, LC, gynecological cancer and GI cancer. The Company is also collaborating with MSD on several global Phase 2 basket studies for sac-TMT as monotherapy or in combination with other agents for multiple solid tumors and those studies are ongoing. Trastuzumab Botidotin (HER2 ADC, A166, 舒泰萊®[1]) In January 2025, an NDA for the treatment of adult patients with HER2+ unresectable or metastatic BC who have received at least one prior anti-HER2 therapy was accepted by the CDE of the NMPA. Trastuzumab botidotin has met the primary endpoints of its pivotal Phase 2 trial for 3L+ and advanced HER2+ BC based on results from the primary analysis, and the NDA has been submitted to the NMPA. The Company has initiated an open, multicenter Phase 2 clinical study of trastuzumab botidotin in the treatment of HER2+ unresectable or metastatic BC that previously received a topoisomerase 1 inhibitor ADC. Other ADC Products SKB315 (CLDN18.2 ADC): the company is conducting a Phase 1b clinical trial of SKB315 and have initiated the exploration in combination with immunotherapy for the treatment of GC/GEJC. Results of a Phase 1 study of SKB315 will be presented at 2025 ESMO Congress in October 2025. SKB410/MK-3120 (Nectin-4 ADC): has shown promising Phase 1 clinical data. MSD, as the partner, has launched the global Phase 1/2 clinical trial of SKB410. SKB571/MK-2750: a novel bsADC that primarily targets various solid tumors such as LC and CRC etc. being developed in collaboration with MSD. The Phase 2 clinical trial in China is to be initiated. SKB518, SKB535/MK-6204 and SKB445: novel ADC drugs with potential FIC targets. The Phase 2 clinical trial for SKB518 and the Phase 1 clinical trials for SKB535 and SKB445 are ongoing in China. The Company has entered into a license and collaboration agreement with MSD to develop SKB535. SKB500 and SKB501: novel ADC drugs with verified targets but differentiated payload-linker strategies. The company been received a clinical trial notice approving the IND application of SKB501 and SKB500, respectively, for advanced solid tumors from the NMPA. SKB107: a RDC drug jointly developed by the Company and the Affiliated Hospital of Southwest Medical University (西南醫科大學附屬醫院) targeting bone metastases in solid tumors. In March 2025, an IND application for SKB107 was approved by the NMPA and the Phase 1 study is ongoing. Non-DC asset advancements are diversifying the innovation pipeline. Tagitanlimab (PD-L1 mAb; A167; 科泰莱®): The first PD-L1 mAb globally to receive authorization for the first-line treatment of NPC. We have received marketing authorization of tagitanlimab in China from NMPA for the treatment of patients with recurrent or metastatic NPC who have failed after prior 2L+ chemotherapy. In January 2025, we received marketing authorization of tagitanlimab used in combination with cisplatin and gemcitabine for the first-line treatment of patients with recurrent or metastatic NPC in China from NMPA. Cetuximab N01 (EGFR mAb; A140; 达泰莱®) An EGFR mAb compared with Cetuximab Solution for Injection (Erbitux®) In February 2025, we received marketing authorization in China from the NMPA for Cetuximab N01 Injection used in combination with FOLFOX or FOLFIRI regimens for first-line treatment of RAS wild-type mCRC. A400/EP0031 (RET inhibitor): The Company is currently conducting pivotal clinical studies for 1L & 2L+ advanced RET+ NSCLC as well as a Phase 1b/2 clinical study for RET+ MTC and solid tumor in China. Through the Company's collaboration and license agreement, Ellipses Pharma is progressing their phase 2 clinical study globally outside of China. SKB378/WIN378 (TSLP mAb): In January 2025, an IND application for SKB378 for the treatment of COPD was approved by the NMPA. The Company's collaboration partner, Windward Bio, has launched the Phase 2 POLARIS trial in patients with asthma. SKB336 (FXI/FXIa mAb): The Phase 1 clinical trial has been completed in China. A296 (STING agonist): A Phase 1 trial is being carried out in China. Commercialization Accelerates: Sales & Market Access Expanding Footprint Sac- TMT (佳泰莱®), tagitanlimab (科泰莱®) and Cetuximab N01 (达泰莱®) have been successively launched, marking the full-scale initiation of commercialization. The Company expects to launch trastuzumab botidotin (舒泰莱®) in the China market and file one NDA for A400 in the second half of 2025. Sales performance: The total commercial sales reached RMB309.8 million for the first half of 2025. Among them, the sales of sac-TMT (佳泰莱®) accounted for 97.6%. At the same time, all accounts receivables from sales of pharmaceutical products were collected within the payment period, ensuring efficient and stable cash flow. Market coverage and academic promotion: Currently, the company's businesses have covered 30 provinces, over 300 prefectures, and over 2,000 hospitals, where over 1,000 hospitals generated sales, and reached tens of thousands of healthcare professionals through various types of marketing campaigns to convey product and medical professional information. In addition, the company has obtained authoritative endorsement for its products from experts in clinical guidelines, providing further support for the commercialization process. Commercialization system: The Company has established a fully-fledged marketing team of over 350 people, with a departmental structure that includes marketing, sales, medical affairs, strategic planning and commercial excellence, among other departments, as well as marketing compliance and KA functions. Through the efficient execution of the marketing team, the company has established relationships with multiple leading commercial and distribution groups, including 60+ Tier 1 distributors and 400+ DTP pharmacies. A hierarchical management system for pharmacy retail has been adopted and trainings have been provided to around 4,500 pharmacists in the first half of 2025. By organizing nationwide pharmacy trainings, the company has significantly enhanced the professionalism of terminal services and improved the ability to provide patients with medication guidance. Market access: In the first half of 2025, sac-TMT (佳泰莱®), tagitanlimab (科泰莱®) and Cetuximab N01 (达泰莱®) have been included in 29, 25 and 15 provincial networks, respectively, ensuring rapid market access through provincial procurement channels. Meanwhile, preparations for the National Reimburesement Drug List (國家醫保藥品目錄) access of marketed products are underway. Currently, sac-TMT (佳泰莱®), tagitanlimab (科泰莱®) and Cetuximab N01 (达泰莱®) have all passed the preliminary formal examination of National Reimbursement Drug List. Meanwhile, to further reduce the burden of patients and implement the concept of inclusive healthcare, the company been proactively facilitating the enrollment of sac-TMT (佳泰莱®) in provincial and prefecture city level Inclusive Insurance (惠民保). As at the end of the Reporting Period, sac-TMT (佳泰莱®) has been enrolled in more than 7 provinces and 20 cities. Global market: Globally, we will continue to pursue a flexible strategy to capture the commercial value in major international markets, through forging synergistic license and collaboration opportunities worldwide. Global Collaboration Network Expansion & Authoritative Industry Recognition In the first half of 2025, the Company continued to expand its global collaboration network and deepen partnerships. Working closely with collaborators, it is advancing clinical research worldwide with the goal of maximizing the global value of its pipeline, delivering high-quality medical solutions to patients, and strengthening its leading position in the biopharmaceutical sector. Collaboration with MSD: As of the date of this announcement, MSD has initiated 14 ongoing Phase 3 global clinical studies of sac-TMT as monotherapy or in combination with pembrolizumab or other agents, for several types of cancer including BC, LC, gynecological cancer and GI cancer. In addition to sac-TMT, the Company is also collaborating with MSD on certain ADC assets including SKB410/MK-3120, SKB571/MK-2750, SKB535/MK-6204, etc. to continuously explore favorable ADC pipeline portfolios. Collaboration with Ellipses Pharma: The Company has deepened its collaboration with Ellipses Pharma on A400/EP0031, which has been cleared by the FDA to progress into Phase 2 clinical development. As of June 30, 2025, Ellipses Pharma had set up a total of 36 clinical sites in the United States, Europe and UAE for EP0031. Collaboration with Windward Bio: In January 2025, the Company and Harbour BioMed had entered into an exclusive license agreement with Windward Bio, under which the Company and Harbour BioMed granted Windward Bio an exclusive license for the research, development, manufacturing and commercialization of SKB378/WIN378 globally (excluding Greater China and several Southeast and West Asian countries). In the first half of 2025, the Company earned high recognition from professional institutions and industry associations for its outstanding corporate management, product innovation, and strong performance in the capital market. In May 2025, the Company received 'Asia's Best Company' award from FinanceAsia (亞洲金融), as well as a series of awards from Extel, including 'Most Honored Company', 'Best Company Board', 'Best CEO', 'Best CFO', 'Best ESG' and etc.. The Company was also awarded 'IRM OF CHINESE LISTED COMPANIES' by Securities Times (證券時報). In July 2025, the Company was recognized with the 'China Pharmaceutical Emerging Innovative Force Award' by the China National Pharmaceutical Industry Information Center (中國醫藥工業信息中心). Additionally, the Company continues to strengthen its ESG strategy and improve its ESG governance structure to support sustainable development. The Company has established a comprehensive three-tier ESG governance structure consisting of the Board of Directors, ESG Working Group and ESG Executive Body. Through the establishment and continuous improvement of the ESG governance structure, the Company comprehensively enhances ESG performance ability. Outlook In the second half of 2025, the Company will continue to advance its differentiated pipelines targeting indications with significant medical needs, innovate and optimize payload-linker strategies, novel DC designs and structures, and expand application to non-oncology diseases. Meanwhile, the Company will further enhance its end-to-end drug development capabilities, advance towards commercialization and actively expand global footprints and strategic partnerships to maximize the value of its pipelines. In addition, the Company will continuously optimize its operation system to become a leading global biopharmaceutical company. About Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (referred to as 'Kelun-Biotech' Stock Code: is a subsidiary of Sichuan Kelun Pharmaceutical Co., Ltd., specializing in the R&D, production, commercialization, and international collaboration of innovative biotechnology and small-molecule drugs. The Company focuses on addressing unmet clinical needs both globally and in China, with a strategic emphasis on major disease areas such as oncology, autoimmune disorders, inflammation, and metabolic diseases. It is dedicated to building an international platform for drug R&D and industrialization, with the aim of becoming a global leader in the innovative drug sector. Currently, Kelun-Biotech has over 30 key innovative drug projects, including 3 projects that have received market approval, 1 project at the NDA stage, and more than 10 projects in clinical trials. The Company has also successfully established its internationally renowned proprietary ADC development platform, OptiDCTM, with 1 ADC project approved for market launch, 1 ADC project at the NDA stage, and several ADC or novel ADC projects in clinical or preclinical development. For more information, please visit the official website: For further information, please contact: Wonderful Sky Financial Group Ltd. Angie Li & Jason Lai Tel: (852) 6150 8598 / (852) 9798 0715 Email: [email protected] View original content to download multimedia: SOURCE Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
